The Overdose Charts Miss This: A Decade of Data Says a Third of Alcohol-Induced Crises Come With Depression Attached

Most people who hear “substance-induced psychiatric disorder” picture something rare and dramatic — a florid episode, a psychiatric hold, a diagnosis that shows up once and gets forgotten. A new study published September 2, 2026, in PLOS Mental Health confirms the “rare” part of that intuition and quietly dismantles the “forgettable” part.

These disorders are a rounding error in the national caseload and a red flag for depression in a third of the people who have them — which means most facilities are set up to miss exactly the pattern that matters most.

Orrin Ware, a researcher at the University of North Carolina at Chapel Hill’s School of Social Work, pulled a decade of admissions data — 2013 through 2022 — from two federal systems: the Mental Health Client-Level Data set and the Treatment Episode Data Set. Together they cover 61.6 million mental-health treatment admissions and 17.4 million substance-use-disorder treatment admissions nationally. Inside that enormous denominator, alcohol- or substance-induced disorders — psychiatric syndromes, like psychosis or major depression, that start during use or withdrawal and are caused directly by the substance rather than existing independently, and that typically resolve within days to weeks once the substance clears — showed up in 439,932 mental-health admissions (0.7% of the total) and 459,817 SUD-treatment admissions (2.7% of that total).

Those percentages are the “rare” half of the finding, and on their own they’d be a footnote. The more useful number is what showed up alongside those diagnoses. Among alcohol-induced disorder cases, alcohol was the primary substance in 68% — unsurprising by definition, but confirming the dataset is capturing what it claims to. Among substance-induced disorder cases more broadly, heroin, other opioids, and synthetic opioids together accounted for 28.8%. And in both categories, a co-occurring depressive disorder diagnosis showed up in roughly one in three alcohol-induced cases and about one in four substance-induced cases.

That co-occurrence rate is the actual news. A syndrome that shows up in under 3% of admissions is easy for a facility to treat as an edge case — something the intake process handles reactively rather than something the screening protocol is built to catch systematically. But if a third of the people who walk in with an alcohol-induced psychiatric crisis are also depressed, and a quarter of people with any substance-induced disorder are too, then “rare” and “safe to under-screen for” are not the same thing. A facility that only screens for depression as a standalone intake question — not specifically asking whether psychiatric symptoms track with use and withdrawal timing — has a real chance of treating the intoxication and missing the depression underneath it, or treating the depression and missing that it’s substance-induced and will resolve differently than primary major depressive disorder.

Ware’s data can’t say why the co-occurrence rate is that high — whether depression makes substance-induced crises more likely, whether substance-induced crises trigger depressive episodes, or whether some third factor drives both. It’s a descriptive study of a decade of intake records, not a causal one, and the paper is appropriately narrow about what it claims. What it does establish, cleanly, is prevalence: this is a large enough overlap, in a large enough national dataset, that “we’ll ask about depression if it comes up” is not an adequate clinical default for the substance-induced-disorder population specifically.

That gap isn’t a surprise to federal guidance — it’s a gap federal guidance has been naming for years without much enforcement teeth behind it. SAMHSA’s own advisory on treating co-occurring disorders, built on its Treatment Improvement Protocol 42, has pushed a “no wrong door” standard for over a decade: anyone presenting for mental health treatment should be routinely screened for substance use, and anyone presenting for substance use treatment should be routinely screened for mental health conditions, regardless of which door they walked through. Ware’s numbers are a decade-long natural experiment in how unevenly that standard actually gets applied. The scale of the underlying population makes the stakes concrete: the 2024 National Survey on Drug Use and Health found 33.0% of U.S. adults — 86.6 million people — had either a mental illness or a substance use disorder in the past year. Even a small, systematically missed slice of that population, multiplied across a system that size, is a lot of people leaving treatment with half the diagnosis addressed.

That gap isn’t a surprise to federal guidance — it’s a gap federal guidance has been naming for years without much enforcement teeth behind it.

For a treatment team, the actionable version of this is small and immediate: when a substance-induced psychiatric diagnosis is on an intake chart, that’s the cue to run a structured depression screen as a matter of protocol, not as an afterthought triggered by the patient volunteering it. The alternative — treating the acute intoxication or withdrawal syndrome and discharging without checking systematically for what’s sitting underneath it in roughly a third of these cases — is exactly the gap this data just quantified, and exactly the gap TIP 42 has been describing since long before this study existed. Ten years of federal admissions records now support making that screen automatic rather than optional. If you’ve ever left a facility feeling like the thing that actually scared you never came up in the paperwork, this is the number that explains why it might not have — and the reason it should.